ES2507097T3 - Composición emulsionada para dilución y composición de vacuna contra el cáncer - Google Patents

Composición emulsionada para dilución y composición de vacuna contra el cáncer Download PDF

Info

Publication number
ES2507097T3
ES2507097T3 ES06701409.2T ES06701409T ES2507097T3 ES 2507097 T3 ES2507097 T3 ES 2507097T3 ES 06701409 T ES06701409 T ES 06701409T ES 2507097 T3 ES2507097 T3 ES 2507097T3
Authority
ES
Spain
Prior art keywords
weight
dilution
composition
ester
emulsified composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06701409.2T
Other languages
English (en)
Inventor
Koichi Saito
Yusuke Okawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NOF Corp
Sumitomo Pharma Co Ltd
Original Assignee
NOF Corp
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NOF Corp, Sumitomo Dainippon Pharma Co Ltd filed Critical NOF Corp
Application granted granted Critical
Publication of ES2507097T3 publication Critical patent/ES2507097T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Uso de una composición emulsionada para dilución de un péptido de antígeno tumoral que tiene 8 a 12 aminoácidos o un dímero del mismo, en donde la composición emulsionada comprende: A) un éster de un ácido graso que tiene 8 a 22 átomos de carbono y un alcohol que tiene 2 a 24 átomos de carbono, teniendo el éster un punto de solidificación no mayor que 10ºC, en 50 a 90% en peso; B) un tensioactivo no iónico constituido por un aducto de triglicérido de hidroxiácido graso con 20 moles de óxido de etileno, en 0,5 a 20% en peso; C) un emulsificante que es un éster parcial de un alcohol polihidroxílico y un ácido graso, siendo el éster parcial líquido a 40ºC, en 0 a 20% en peso; y D) agua en 5 a 20% en peso.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
E06701409
25-09-2014
Tabla 10
Ejemplo Comparativo
11
12 13 14 15
Composición emulsionada número
46 47 48 49 50
Oleato de etilo
70,0 70,0 70,0 70,0 70,0
Polioxietilen(160) polioxipropilen(30) glicol
3,0 - - - -
Polioxietilen(20) polioxipropilen(20) glicol
- 3,0 - - -
Polioxietilen (6) monooleato de sorbitán
- - 3,0 - -
Polioxietilen (6) tetraoleato de sorbitol
- - - 3,0 -
Polioxietilen (30) tetraoleato de sorbitol
- - - - 3,0
Sesquioleato de sorbitán
6,0 6,0 6,0 6,0 6,0
Monooleato de glicerina
6,0 6,0 6,0 6,0 6,0
Agua tamponada con fosfato (pH 7,4)
15,0 15,0 15,0 15,0 15,0
Cambio de estado después de dejar en reposo a la temperatura ambiente durante 24 horas
Separado Separado Separado Separado Separado
Tabla 11
imagen16
17
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22

Claims (1)

  1. imagen1
    imagen2
ES06701409.2T 2005-01-19 2006-01-19 Composición emulsionada para dilución y composición de vacuna contra el cáncer Active ES2507097T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005012140 2005-01-19
JP2005012140 2005-01-19
PCT/JP2006/301171 WO2006078059A1 (ja) 2005-01-19 2006-01-19 希釈用乳化組成物および癌ワクチン組成物

Publications (1)

Publication Number Publication Date
ES2507097T3 true ES2507097T3 (es) 2014-10-14

Family

ID=36692424

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06701409.2T Active ES2507097T3 (es) 2005-01-19 2006-01-19 Composición emulsionada para dilución y composición de vacuna contra el cáncer

Country Status (9)

Country Link
US (2) US8178102B2 (es)
EP (2) EP2687203A1 (es)
JP (1) JP5084268B2 (es)
KR (1) KR101322586B1 (es)
CN (1) CN101111258B (es)
AU (1) AU2006206973C1 (es)
CA (1) CA2595063C (es)
ES (1) ES2507097T3 (es)
WO (1) WO2006078059A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8178102B2 (en) * 2005-01-19 2012-05-15 Dainippon Sumitomo Pharma Co., Ltd. Emulsified composition for dilution and cancer vaccine composition
KR100900837B1 (ko) 2007-12-07 2009-06-04 (주)두비엘 리포펩타이드와 폴리(ｉ:ｃ)를 아쥬반트로 포함하는 강력한백신 조성물
US20140234377A1 (en) * 2013-02-05 2014-08-21 Nitto Denko Corporation Vaccine composition for mucosal administration
EP2762154A3 (en) * 2013-02-05 2015-01-21 Nitto Denko Corporation Vaccine composition for transdermal administration
DK2982681T3 (en) 2013-03-29 2018-12-10 Sumitomo Dainippon Pharma Co Ltd WT1 ANTIGENPEPTIDKONJUGATVACCINE
US10588952B2 (en) 2013-03-29 2020-03-17 Sumitomo Dainippon Pharma Co., Ltd. Conjugate vaccine using trimming function of ERAP1
WO2018101309A1 (ja) 2016-11-30 2018-06-07 大日本住友製薬株式会社 Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
EP3604325A4 (en) 2017-03-30 2021-01-13 Sumitomo Dainippon Pharma Co., Ltd. WT1 CANCER ANTIGEN PEPTIDE AND PEPTIDE CONJUGATE BODY WITH IT
CA3113212A1 (en) 2018-09-28 2020-04-02 Sumitomo Dainippon Pharma Co., Ltd. Injectable composition
WO2020204173A1 (ja) 2019-04-05 2020-10-08 大日本住友製薬株式会社 水溶性アジュバントおよびそれを含有する組成物
WO2020204172A1 (ja) 2019-04-05 2020-10-08 大日本住友製薬株式会社 水溶性アジュバント
US20230183316A1 (en) 2020-05-12 2023-06-15 Sumitomo Pharma Co., Ltd. Pharmaceutical composition for treating cancer
EP4385519A1 (en) 2021-08-12 2024-06-19 International Institute of Cancer Immunology, Inc. Pharmaceutical composition and method for treatment or prevention of cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0247474A (ja) 1988-08-04 1990-02-16 Aisan Ind Co Ltd 立体駐車装置
JPH085401B2 (ja) * 1990-05-18 1996-01-24 株式会社丸山製作所 自走車両のブレーキ装置
WO1992018147A1 (en) * 1991-04-19 1992-10-29 Affinity Biotech, Inc. Convertible microemulsion formulations
JPH0620071A (ja) 1992-07-03 1994-01-28 Sharp Corp データ駆動型情報処理装置
FR2702373B1 (fr) 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
US5744137A (en) 1995-02-06 1998-04-28 The United States Of America As Represented By The Secretary Of The Agriculture Oil emulsion vaccines prepared with animal, vegetable, and synthetic oils using a mixture of nonionic surfactants
ES2277339T3 (es) * 1995-11-30 2007-07-01 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Vacuna con adyuvante de aceite y metodo para su preparacion.
JP4104186B2 (ja) 1995-11-30 2008-06-18 財団法人化学及血清療法研究所 オイルアジュバントワクチンおよびその調製方法
JP4113990B2 (ja) 1996-07-05 2008-07-09 宮崎県 抗癌剤含有乳化製剤及びその製造方法
WO1999053947A1 (fr) 1998-04-20 1999-10-28 Shionogi & Co., Ltd. PROMOTEURS DE LA MIGRATION DE Th2 CONTENANT DES EMULSIONS EAU-DANS-HUILE
NZ512302A (en) 1998-12-21 2003-08-29 Akzo Nobel Nv Method to produce inactivated w/o emulsion adjuvated vaccines
FR2800280B1 (fr) 1999-10-29 2003-09-19 Seppic Sa Nouvelle composition vaccinale et utilisation d'agents tensioactifs comme adjuvants d'immunite
JP2001131087A (ja) 1999-11-05 2001-05-15 Chemo Sero Therapeut Res Inst オイルアジュバントワクチン
AU2003262094A1 (en) 2002-09-12 2004-04-30 Haruo Sugiyama Cancer antigen peptide preparation
EP2263687B1 (en) * 2002-12-27 2015-03-25 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions containing phospholipid
US8178102B2 (en) * 2005-01-19 2012-05-15 Dainippon Sumitomo Pharma Co., Ltd. Emulsified composition for dilution and cancer vaccine composition

Also Published As

Publication number Publication date
WO2006078059A1 (ja) 2006-07-27
JP5084268B2 (ja) 2012-11-28
CA2595063A1 (en) 2006-07-27
CN101111258A (zh) 2008-01-23
CA2595063C (en) 2014-07-08
KR101322586B1 (ko) 2013-10-25
EP1844789A1 (en) 2007-10-17
EP2687203A1 (en) 2014-01-22
EP1844789A4 (en) 2009-10-28
JPWO2006078059A1 (ja) 2008-06-19
CN101111258B (zh) 2011-07-06
US8178102B2 (en) 2012-05-15
US20090136572A1 (en) 2009-05-28
AU2006206973B2 (en) 2010-09-30
AU2006206973A1 (en) 2006-07-27
EP1844789B8 (en) 2014-10-08
US20120237569A1 (en) 2012-09-20
AU2006206973C1 (en) 2012-06-28
EP1844789B1 (en) 2014-07-23
KR20070104610A (ko) 2007-10-26

Similar Documents

Publication Publication Date Title
ES2507097T3 (es) Composición emulsionada para dilución y composición de vacuna contra el cáncer
ES2553085T3 (es) Procedimiento para la preparación de 2,2-difluoroetanol
AR025749A1 (es) Vacunas
ES2575549T3 (es) Comprimido de melatonina y métodos de preparación y uso
AR055503A1 (es) Anticorrosivo para liquidos funcionales concentrado miscible con agua y su uso
AR053360A1 (es) Formulaciones novedosas de vacunas
ES2512141T3 (es) Análogo peptídico de oxintomodulina
ES2486675T3 (es) Análogo de péptido de oxintomodulina
ES2531646T3 (es) Composiciones de emulsión farmacéuticas con bajo contenido de aceite que comprenden progestágeno
ES2550634T3 (es) Uso de nanocristales para un balón de suministro de fármaco
ES2686494T3 (es) Composición oleosa volátil
CL2004000691A1 (es) Emulsion submicrometrica de aceite en agua de utilidad como adyuvante de vacuna que comprende un aceite, un tensoactivo y un componente acuoso y tamano medio de gota inferior a 1 um; procedimiento para preparar la emulsio; composicion de vacuna que c
ES2528412T3 (es) Espumas de alimentos y bebidas
BR112014031837A2 (pt) formulações de progesterona
CO6251369A2 (es) Vacuna de influenza de emulsion de aceite en agua
ES2721148T3 (es) Composiciones farmacéuticas de paclitaxel, análogos de paclitaxel o conjugados de paclitaxel y métodos relacionados de preparación y uso
AR079556A1 (es) Formacion de anticuerpos
ES2497667T3 (es) Sistema de emulsificación para usar en cosméticos
AR062952A1 (es) Inhibicion de la maduracion ostwald en formulaciones quimicas
ES2527454T3 (es) El uso de derivados del péptido Wnt5-a para el tratamiento de melanoma y cáncer gástrico
ZA202106232B (en) Emulsifier and emulsions
CL2016002400A1 (es) Formulación para higiene personal
CL2011002994A1 (es) Construccion de proteina que comprende polipeptido casb7439; composicion inmunogenica que comprende dicha construccion; uso de la composicion porque sirve para inducir respuesta inmunitaria al casb7439 en un animal.
CY1114046T1 (el) Φαρμακευτικη συνθεση που περιεχει φουροϊκη μομεταζονη
CL2022002020A1 (es) Compuesto de 3'-cetoglucósido para la liberación lenta de un alcohol volátil